Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Effects of Crushing Prasugrel in STEMI Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with ST-elevation myocardial infarction undergoing primary PCI~* Age between 18 and 75 years old~Exclusion criteria:~* Age \>75 years~* Weight \<60 Kg~* On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in past 7 days~* Known allergies to aspirin or prasugrel~* Considered at high risk for bleeding~* History of ischemic or hemorrhagic stroke or transient ischemic attack~* On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban, apixaban)~* Treatment with IIb/IIIa glycoprotein inhibitors~* Fibrinolytics within 24 hours~* Known blood dyscrasia or bleeding diathesis~* Known platelet count \<80x106/mL~* Known hemoglobin \<10 g/dL~* Active bleeding~* Hemodynamic instability~* Known creatinine clearance \<30 mL/minute~* Known severe hepatic dysfunction~* Pregnant females\*~  * Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel crush (Type: EXPERIMENTAL): Prasugrel 60mg loading dose as crushed tablets
- Prasugrel tablets (Type: ACTIVE_COMPARATOR): Prasugrel 60 mg loading dose as whole tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).